Literature DB >> 26542879

Pharmacogenomics of preterm birth prevention and treatment.

T A Manuck1,2.   

Abstract

UNLABELLED: Pharmacogenomics and personalised medicine incorporate genetic factors, historical data, and environmental exposures to predict individual variation in response to medications. The study of pharmacology and pharmacogenomics is challenging in obstetrics, and our knowledge in this area lags behind other disciplines of medicine. Some preliminary data, however, suggest that some of the interindividual variation seen in response to medications given for the prevention (progesterone) and the treatment (nifedipine, terbutaline, and others) of preterm labour may be caused by pharmacogenomic effects. A comprehensive approach, integrating clinical data, environmental factors, including concomitant medications and genotype, to optimise the prevention and treatment strategies for preterm birth, is urgently needed. TWEETABLE ABSTRACT: Some of the variation to meds for prematurity prevention/treatment may arise from pharmacogenomic effects.
© 2015 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Personalised medicine; pharmacogenomics; prematurity prevention; preterm birth; progesterone; tocolysis

Mesh:

Year:  2015        PMID: 26542879      PMCID: PMC4729635          DOI: 10.1111/1471-0528.13744

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  45 in total

Review 1.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

Review 2.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

3.  17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.

Authors:  William A Grobman; Elizabeth A Thom; Catherine Y Spong; Jay D Iams; George R Saade; Brian M Mercer; Alan T N Tita; Dwight J Rouse; Yoram Sorokin; Ronald J Wapner; Kenneth J Leveno; Sean Blackwell; M Sean Esplin; Jorge E Tolosa; John M Thorp; Steve N Caritis; J Peter Van Dorsten
Journal:  Am J Obstet Gynecol       Date:  2012-09-17       Impact factor: 8.661

4.  Preterm birth in rats produced by the synergistic action of a nitric oxide inhibitor (NG-nitro-L-arginine methyl ester) and an antiprogestin (onapristone).

Authors:  C Yallampalli; I Buhimschi; K Chwalisz; R E Garfield; Y L Dong
Journal:  Am J Obstet Gynecol       Date:  1996-07       Impact factor: 8.661

5.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Transdermal nitroglycerin for the treatment of preterm labor: a systematic review and metaanalysis.

Authors:  Agustín Conde-Agudelo; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2013-07-24       Impact factor: 8.661

7.  Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.

Authors:  Tracy A Manuck; W Scott Watkins; Barry Moore; M Sean Esplin; Michael W Varner; G Marc Jackson; Mark Yandell; Lynn Jorde
Journal:  Am J Obstet Gynecol       Date:  2014-03-01       Impact factor: 8.661

8.  A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.

Authors:  Dwight J Rouse; Deborah G Hirtz; Elizabeth Thom; Michael W Varner; Catherine Y Spong; Brian M Mercer; Jay D Iams; Ronald J Wapner; Yoram Sorokin; James M Alexander; Margaret Harper; John M Thorp; Susan M Ramin; Fergal D Malone; Marshall Carpenter; Menachem Miodovnik; Atef Moawad; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Oded Langer; Steve N Caritis; James M Roberts
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

9.  VAAST 2.0: improved variant classification and disease-gene identification using a conservation-controlled amino acid substitution matrix.

Authors:  Hao Hu; Chad D Huff; Barry Moore; Steven Flygare; Martin G Reese; Mark Yandell
Journal:  Genet Epidemiol       Date:  2013-07-08       Impact factor: 2.135

10.  Effects of β2-adrenergic receptor gene polymorphisms on ritodrine therapy in pregnant women with preterm labor: prospective follow-up study.

Authors:  Jin Young Park; Na Ra Lee; Kyung Eun Lee; Sunny Park; Young Ju Kim; Hye Sun Gwak
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

View more
  5 in total

1.  Effect of dydrogesterone and progesterone on threatened miscarriage due to corpus luteum insufficiency.

Authors:  Caiyu Lou; Caiwen Wang; Qiang Zhao; Fenyuan Jin
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Prenatal pharmacogenomics: a promising area for research.

Authors:  E H Dorfman; E Y Cheng; M F Hebert; K E Thummel; W Burke
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

Review 3.  Obesity in pregnancy: a novel concept on the roles of adipokines in uterine contractility.

Authors:  Judit Hajagos-Tóth; Eszter Ducza; Reza Samavati; Sandor G Vari; Robert Gaspar
Journal:  Croat Med J       Date:  2017-04-14       Impact factor: 1.351

4.  Refining Pharmacologic Research to Prevent and Treat Spontaneous Preterm Birth.

Authors:  Tracy A Manuck
Journal:  Front Pharmacol       Date:  2017-03-15       Impact factor: 5.810

5.  Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges.

Authors:  Susanne B Haga
Journal:  Pharmgenomics Pers Med       Date:  2019-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.